Entera Bio Ltd (ENTX)

Currency in USD
2.860
-0.060(-2.05%)
Closed·
2.8600.000(0.00%)
·
Earnings results expected in 10 days
ENTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.8002.900
52 wk Range
0.9104.200
Key Statistics
Prev. Close
2.92
Open
2.9
Day's Range
2.8-2.9
52 wk Range
0.91-4.2
Volume
232.46K
Average Volume (3m)
1.9M
1-Year Change
28.8288%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.750
Upside
+240.91%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Entera Bio Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.750
(+240.91% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy11.00+284.62%-New CoverageSep 25, 2026
Cantor Fitzgerald
Buy---New CoverageSep 22, 2026
Leerink
Buy9.00+214.69%-New CoverageSep 18, 2026
H.C. Wainwright
Buy9.00+214.69%-MaintainJun 24, 2026
H.C. Wainwright
Buy9.00+214.69%10.00MaintainApr 27, 2026

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-0.14 / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ENTX Income Statement

Compare ENTX to Peers and Sector

Metrics to compare
ENTX
Peers
Sector
Relationship
P/E Ratio
−29.8x−1.9x−0.3x
PEG Ratio
0.75−0.030.00
Price/Book
69.9x2.1x2.6x
Price / LTM Sales
-17.1x2.9x
Upside (Analyst Target)
239.7%1,061.3%65.4%
Fair Value Upside
Unlock29.6%8.9%Unlock

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
178.58K0.10%521.44K
Other Institutional Investors
122.36M70.36%357.30M
Public Companies & Retail Investors
51.38M29.54%150.03M
Total
173.92M100.00%507.85M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BVF Partners L.P.9.80%17,052,89349,794
TCG Crossover Fund III, L.P.7.05%12,254,90135,784

People Also Watch

89.680
KOD
+2.34%
14.45
BHVN
+4.11%
6.160
AGEN
-2.69%
69.10
CDNA
-0.16%
1.290
QTEX
-7.19%

FAQ

What Is the Entera Bio (ENTX) Stock Price Today?

The Entera Bio stock price today is 2.860 USD.

What Stock Exchange Does Entera Bio Trade On?

Entera Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Entera Bio?

The stock symbol for Entera Bio is "ENTX."

What Is the Entera Bio Market Cap?

As of today, Entera Bio market cap is 507.850M USD.

What Is Entera Bio's Earnings Per Share (TTM)?

The Entera Bio EPS (TTM) is -0.35.

When Is the Next Entera Bio Earnings Date?

Entera Bio will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is ENTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Entera Bio Stock Split?

Entera Bio has split 0 times.

How Many Employees Does Entera Bio Have?

Entera Bio has 21 employees.

What is the current trading status of Entera Bio (ENTX)?

As of Oct 26, 2026, Entera Bio (ENTX) is trading at a price of 2.860 USD, with a previous close of 2.920 USD. The stock has fluctuated within a day range of 2.800 USD to 2.900 USD, while its 52-week range spans from 0.910 USD to 4.200 USD.

What Is Entera Bio (ENTX) Price Target According to Analysts?

The average 12-month price target for Entera Bio is 9.750 USD, with a high estimate of 11 USD and a low estimate of 9 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +240.91% Upside potential.

What Is the ENTX Premarket Price?

ENTX's last pre-market stock price is 2.900 USD. The pre-market share volume is 20.000, and the stock has decreased by -0.020, or -0.680%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.